IBD Evidence

Article

What causes IBD? Genetics, environment and rising incidence

Updated 4 min read 36 citations

Wire endoscopy snare used for upper gastrointestinal and colonic polypectomy
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Neither genetics nor environment explains inflammatory bowel disease on its own. The genetics tells you who is susceptible; the epidemiology tells you that susceptibility alone cannot be the whole story, because the disease's global map has moved too fast for genes to explain.

What genetics actually shows

Genome-wide association studies have identified a substantial number of loci associated with IBD susceptibility. A meta-analysis of association data identified 38 susceptibility loci and highlighted genetic risk shared across populations and, notably, shared in part with other immune-mediated diseases [26]. A separate genome-wide association study implicated immune activation of multiple integrin genes specifically [25] — a mechanistically interesting result, since integrin-blocking drugs (the anti-integrin biologic class covered on our treatment page) work by interrupting exactly the leucocyte-trafficking pathway these genes sit in.

The practical takeaway from the genetics is narrower than people expect. IBD is not a single-gene, Mendelian-inherited disease — it is polygenic, with many loci each contributing a small amount of risk. Having a first-degree relative with IBD raises risk above the general population, but the great majority of people who carry IBD-associated genetic variants never develop the disease. Genetics sets a susceptibility threshold; something else decides whether that threshold gets crossed.

Why genetics can't be the whole story

The genetic architecture of a population does not change over a few decades. The global incidence of IBD has. A 2025 analysis in Nature traces IBD's incidence across what it terms epidemiologic stages — low incidence, an acceleration phase as incidence rises sharply, then a compositional prevalence equilibrium phase where incidence plateaus but the number of people living with the disease keeps climbing because it is chronic [36]. Regions newly industrialising today are moving through the acceleration phase that Western Europe and North America moved through across the twentieth century.

This pattern was documented earlier in a systematic review of population-based studies on worldwide incidence and prevalence [24], and a further review specifically addressing epidemiology across the ages in the era of advanced therapies situates the current global picture [34]. A systematic review focused on paediatric-onset IBD found the same accelerating trend specifically in children and adolescents [16], and hospitalisation trends across the same period were characterised in a further systematic review with temporal analyses [7].

A geographic and temporal pattern that tracks industrialisation rather than genetic drift is the strongest available argument that something about how a population lives — not just how it's born — is doing a substantial part of the causal work.

The environmental candidates

An umbrella review of meta-analyses examined environmental risk factors for IBD directly, pulling together the evidence across many individual exposure studies into one synthesis [21]. The honest summary of this literature is that several candidates have supporting evidence of varying strength, and none has been shown to be sufficient on its own — consistent with a disease that plausibly requires a genetically susceptible individual to encounter a particular combination of exposures.

The one asset: how the pieces fit together

Factor categoryWhat's establishedWhat isn't
Genetic susceptibilityDozens of contributing loci identified; risk clusters in families and shares mechanisms with other immune diseaseNo single gene is necessary or sufficient; most genetically susceptible people never develop IBD
Geographic/temporal patternIncidence rises sharply as regions industrialise, then plateaus while prevalence keeps climbingThe pattern shows environment matters; it does not by itself identify which exposure matters most
Individual environmental exposuresAn umbrella review has synthesised the exposure literature across many candidate factorsNo single environmental factor is established as necessary or sufficient on its own
The interactionPlausible and consistent with the overall data pattern: susceptibility plus exposureNot directly measurable with current study designs at the individual level

Why this matters practically

None of this changes management. It does not identify a food to avoid, a lifestyle change guaranteed to prevent flares, or a test that predicts individual risk with useful precision. What it does explain is two things patients are frequently told inconsistently: that IBD is not "caused" by diet or stress in any simple sense (genetics and population-level environmental shifts are doing far more of the causal work than day-to-day choices), and that it is also not purely genetic bad luck (the rising incidence in newly industrialising regions rules that out on its own). Both of those reframings tend to reduce the guilt patients report around "what did I do to cause this" — a question the evidence base does not actually support asking of any single behaviour.

Common questions

Is IBD hereditary? Will my children get it?
Risk is elevated in first-degree relatives of someone with IBD, but the great majority of relatives never develop it. It is a susceptibility gene pattern, not a Mendelian inherited disease.
Did something I ate or did cause my IBD?
No single dietary or lifestyle factor has been established as a sufficient cause. The evidence points to a combination of genetic susceptibility and population-level environmental exposures playing out over years, not an identifiable individual trigger.
Why is IBD becoming more common in countries where it used to be rare?
This tracks industrialisation closely enough that it's one of the strongest arguments for an environmental component — genes do not change fast enough to explain it, and the pattern has now been documented across multiple regions and time periods.
If genetics only explains susceptibility, what's the actual trigger?
Not established with precision. Candidate environmental exposures have been synthesised in umbrella review evidence, but no single factor has been shown to be necessary or sufficient — this remains an open area of research rather than a solved question.
Three camera capsules used to image the oesophagus, small intestine and large intestine
Swallowed capsules photograph stretches of small bowel that a conventional endoscope cannot reach. Dr.HH.Krause · CC BY-SA 3.0 · Wikimedia Commons
The evidence behind this page A stacked bar showing the composition of the 36 publications cited on this page by study type. 2663meta-analysis (26)randomised trial (6)review (3)other (1)
36 publications, 2015–2026. That is a mix with both trials and syntheses in it, which is the position from which a claim about cause is reasonable. Source: this page’s own citation list, below.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  2. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  3. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  4. Using Diet to Treat Inflammatory Bowel Disease: A Systematic Review Gleave A, Shah A, Tahir U, et al. · The American journal of gastroenterology · 2025 · Systematic review DOIPubMed 39056556
  5. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  6. Acute severe ulcerative colitis trials: the past, the present and the future Honap S, Jairath V, Sands BE, et al. · Gut · 2024 · Systematic review DOIPubMed 38834296Full text
  7. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses Buie MJ, Quan J, Windsor JW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · Meta-analysis DOIPubMed 35863682
  8. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  9. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  10. High-Fiber Diet and Crohn's Disease: Systematic Review and Meta-Analysis Serrano Fernandez V, Seldas Palomino M, Laredo-Aguilera JA, et al. · Nutrients · 2023 · Meta-analysis DOIPubMed 37513532Full text
  11. Dietary Interventions in Ulcerative Colitis: A Systematic Review of the Evidence with Meta-Analysis Herrador-López M, Martín-Masot R, Navas-López VM · Nutrients · 2023 · Meta-analysis DOIPubMed 37836478Full text
  12. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  13. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  14. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  15. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  16. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review Kuenzig ME, Fung SG, Marderfeld L, et al. · Gastroenterology · 2022 · Systematic review DOIPubMed 34995526
  17. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  18. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease Sinopoulou V, Gordon M, Akobeng AK, et al. · The Cochrane database of systematic reviews · 2021 · Systematic review DOIPubMed 34844288Full text
  19. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  20. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  21. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses Piovani D, Danese S, Peyrin-Biroulet L, et al. · Gastroenterology · 2019 · Meta-analysis DOIPubMed 31014995
  22. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  23. ESPEN guideline: Clinical nutrition in inflammatory bowel disease Forbes A, Escher J, Hébuterne X, et al. · Clinical nutrition (Edinburgh, Scotland) · 2017 · Systematic review DOIPubMed 28131521
  24. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Ng SC, Shi HY, Hamidi N, et al. · Lancet (London, England) · 2017 · Systematic review DOIPubMed 29050646
  25. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  26. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text
  27. Whole Food Diet Induces Remission in Children and Young Adults With Mild to Moderate Crohn's Disease and Is More Tolerable Than Exclusive Enteral Nutrition: A Randomized Controlled Trial Aharoni-Frutkoff Y, Plotkin L, Pollak D, et al. · Gastroenterology · 2025 · Randomised controlled trial DOIPubMed 40553742
  28. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Ferrante M, D'Haens G, Jairath V, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39581202
  29. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial Yanai H, Levine A, Hirsch A, et al. · The lancet. Gastroenterology & hepatology · 2022 · Randomised controlled trial DOIPubMed 34739863
  30. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  31. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial Levine A, Wine E, Assa A, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 31170412
  32. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. · The New England journal of medicine · 2019 · Randomised controlled trial DOIPubMed 31553834
  33. Chronic, Noninfectious Diarrhea: A Review Singh P, Lee A, Sheth NM, et al. · JAMA · 2026 · Review DOIPubMed 41770539
  34. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Caron B, Honap S, Peyrin-Biroulet L · Journal of Crohn's & colitis · 2024 · Review DOIPubMed 39475082Full text
  35. Mild Crohn's Disease: Definition and Management Claytor J, Kumar P, Ananthakrishnan AN, et al. · Current gastroenterology reports · 2023 · Review DOIPubMed 36753033
  36. Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. · Nature · 2025 · Journal article DOIPubMed 40307548Full text